Related Experiment Video

Updated: Apr 14, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.5K

Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells

Tanmay M Shekhar1, Maja M Green2, David M Rayner1

  • 1Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora 3083, Australia.

Mutation Research
|April 29, 2015
PubMed

Insights

New cancer therapies, including BH3-mimetics and IAP antagonists, show minimal genotoxic activity, potentially reducing secondary cancers in survivors. Unlike conventional treatments, these agents directly induce apoptosis, avoiding DNA damage and associated risks.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Conventional chemotherapy and radiotherapy can cause permanent genomic damage, leading to side effects like secondary malignancies in cancer survivors.
  • Novel apoptosis-inducing agents, such as death ligand mimics and Bcl-2/IAP antagonists, offer a promising alternative by directly targeting cancer cell death pathways.
  • Previous studies indicated that some apoptosis-inducing agents, like TRAIL, could still provoke DNA damage in surviving cells at clinically relevant concentrations.

Purpose of the Study:

  • To investigate the genotoxic potential of BH3-mimetic ABT-737 and IAP antagonists (LCL161, AT-406) as direct apoptosis-inducing agents.
  • To compare the mutagenic capacity of these novel agents with conventional DNA-damaging therapies.
  • To assess whether these agents could minimize or eliminate the risk of secondary cancers associated with DNA damage.

Main Methods:

  • Utilized cell line model systems to evaluate the mutagenic capacity of ABT-737, LCL161, and AT-406.
  • Assessed DNA damage induction at concentrations relevant to in vivo clinical settings.
  • Investigated the signaling pathways involved in DNA damage, including Bax/Bak-dependent and independent mechanisms.

Main Results:

  • IAP antagonists (LCL161, AT-406) demonstrated negligible genotoxic activity.
  • ABT-737 required high doses to induce DNA damage, which involved Bax/Bak-independent signaling and exceeded plasma concentrations observed in animal studies.
  • These findings suggest that IAP antagonists are not mutagenic, and BH3-mimetics may have limited genotoxicity at therapeutic levels.

Conclusions:

  • IAP antagonists show promise as cancer therapeutics with minimal risk of inducing secondary mutations.
  • BH3-mimetics may also offer an advantage over conventional therapies by avoiding significant DNA damage at effective concentrations.
  • These direct apoptosis-inducing agents could potentially reduce mutation-related illnesses in cancer survivors compared to traditional DNA-damaging treatments.
Keywords:
Bcl-2DNA damageGenotoxicIAPLate effectsSecond malignant neoplasms

More Related Videos

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling10:00

Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling

Published on: October 28, 2014

29.2K
Identifying Protein-protein Interaction Sites Using Peptide Arrays07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.8K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K